Announced July 25, Dr. Reshma Kewalramani will be promoted to president and CEO of Vertex Pharmaceuticals. She is currently the chief medical officer for the company and was previously a practicing nephrologist who earned her medical doctorate at Boston University and trained at Bigham & Women’s Hospital.
Dr. Kewalramani will be the first woman to run a large biotechnology firm. Vortex’s share price “rose 360% and its sales doubled to $3 billion annually” under the previous CEO, largely due the company’s pharmaceuticals used to treat cystic fibrosis.
Announced July 25, Dr. Reshma Kewalramani will be promoted to president and CEO of Vertex Pharmaceuticals. She is currently the chief medical officer for the company and was previously a practicing nephrologist who earned her medical doctorate at Boston University and trained at Bigham & Women’s Hospital.
Dr. Kewalramani will be the first woman to run a large biotechnology firm. Vortex’s share price “rose 360% and its sales doubled to $3 billion annually” under the previous CEO, largely due the company’s pharmaceuticals used to treat cystic fibrosis.
In an interview with STAT, Dr. Kewalramani stated: “we really have thought long and hard about who we are now and who we want to be in the future… and I am excited, I am grateful, and I am ready to take our strategy and execute for some time to come.”
Dr. Kewalramani was a founding member of the Kidney Health Initiative (KHI) Board of Directors. KHI is a public-private partnership between the American Society of Nephrology and the US Food and Drug Administration (FDA). Established in 2012, the partnership between KHI and FDA is valuable to help foster the development of new products to improve the lives of people living with kidney disease.
Read more on STAT .
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory